Calidi Biotherapeutics, Inc. (CLDI)
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $45.0K
- Net income
- -$19.9M
- Total assets
- $8.9M
- Market cap
- $3.3M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $20.2M
- Operating income
- -$20.2M
- Income tax
- $15.0K
- Net income
- -$20.1M
- EPS (basic)
- $-5.95
- EPS (diluted)
- $-5.95
Balance sheet
- Total assets
- $8.9M
- Current assets
- $6.3M
- Total liabilities
- $5.1M
- Current liabilities
- $3.9M
- Shareholders’ equity
- $3.8M
Cash flow
- Operating cash flow
- -$21.3M
- Investing cash flow
- -$170.0K
- Financing cash flow
- $17.5M
- Net cash flow
- -$4.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.3M
- EPS (diluted)
- $-5.95
- Shares outstanding
- 32.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2023
Calidi Biotherapeutics, Inc. (CLDI) Stock Price
- Reported a net loss of $19.9M in FY2022.
- Trading 99% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Calidi Biotherapeutics, Inc..
Write a review
News about Calidi Biotherapeutics, Inc.
News & sentiment via Polygon.io
Calidi Biotherapeutics, Inc.: frequently asked questions
Is Calidi Biotherapeutics, Inc. an American company?
Calidi Biotherapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Calidi Biotherapeutics, Inc. headquartered?
Calidi Biotherapeutics, Inc. is headquartered in San Diego, California, United States.
Is Calidi Biotherapeutics, Inc. publicly traded?
Yes — Calidi Biotherapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol CLDI on the NYSE.
What does Calidi Biotherapeutics, Inc. do?
Calidi Biotherapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
